155 related articles for article (PubMed ID: 9369323)
1. Effects of amisulpride, an atypical antipsychotic which blocks preferentially presynaptic dopamine autoreceptors, on integrated functional cerebral activity in the rat.
Cudennec A; Fage D; Bénavidès J; Scatton B
Brain Res; 1997 Sep; 768(1-2):257-65. PubMed ID: 9369323
[TBL] [Abstract][Full Text] [Related]
2. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
Schoemaker H; Claustre Y; Fage D; Rouquier L; Chergui K; Curet O; Oblin A; Gonon F; Carter C; Benavides J; Scatton B
J Pharmacol Exp Ther; 1997 Jan; 280(1):83-97. PubMed ID: 8996185
[TBL] [Abstract][Full Text] [Related]
3. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B
J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
[TBL] [Abstract][Full Text] [Related]
4. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
Bressan RA; Erlandsson K; Jones HM; Mulligan R; Flanagan RJ; Ell PJ; Pilowsky LS
Am J Psychiatry; 2003 Aug; 160(8):1413-20. PubMed ID: 12900302
[TBL] [Abstract][Full Text] [Related]
5. Imaging brain gene expression profiles by antipsychotics: region-specific action of amisulpride on postsynaptic density transcripts compared to haloperidol.
de Bartolomeis A; Marmo F; Buonaguro EF; Rossi R; Tomasetti C; Iasevoli F
Eur Neuropsychopharmacol; 2013 Nov; 23(11):1516-29. PubMed ID: 23357084
[TBL] [Abstract][Full Text] [Related]
6. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia.
Xiberas X; Martinot JL; Mallet L; Artiges E; Canal M; Loc'h C; Mazière B; Paillère-Martinot ML
J Clin Psychopharmacol; 2001 Apr; 21(2):207-14. PubMed ID: 11270918
[TBL] [Abstract][Full Text] [Related]
7. Amisulpride: from animal pharmacology to therapeutic action.
Scatton B; Claustre Y; Cudennec A; Oblin A; Perrault G; Sanger DJ; Schoemaker H
Int Clin Psychopharmacol; 1997 May; 12 Suppl 2():S29-36. PubMed ID: 9218165
[TBL] [Abstract][Full Text] [Related]
8. Striatal D2/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study.
Meisenzahl EM; Schmitt G; Gründer G; Dresel S; Frodl T; la Fougère C; Scheuerecker J; Schwarz M; Boerner R; Stauss J; Hahn K; Möller HJ
Pharmacopsychiatry; 2008 Sep; 41(5):169-75. PubMed ID: 18763218
[TBL] [Abstract][Full Text] [Related]
9. Amisulpride: a review of its use in the management of schizophrenia.
Curran MP; Perry CM
Drugs; 2001; 61(14):2123-50. PubMed ID: 11735643
[TBL] [Abstract][Full Text] [Related]
10. Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients.
Bressan RA; Erlandsson K; Spencer EP; Ell PJ; Pilowsky LS
Psychopharmacology (Berl); 2004 Sep; 175(3):367-73. PubMed ID: 14997280
[TBL] [Abstract][Full Text] [Related]
11. Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine.
Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
Schizophr Res; 2008 Oct; 105(1-3):224-35. PubMed ID: 18710798
[TBL] [Abstract][Full Text] [Related]
12. Non-uniform blockade of intrastriatal D2/D3 receptors by risperidone and amisulpride.
Stone JM; Bressan RA; Erlandsson K; Ell PJ; Pilowsky LS
Psychopharmacology (Berl); 2005 Aug; 180(4):664-9. PubMed ID: 15719226
[TBL] [Abstract][Full Text] [Related]
13. Spotlight on amisulpride in schizophrenia.
Curran MP; Perry CM
CNS Drugs; 2002; 16(3):207-11. PubMed ID: 11888341
[TBL] [Abstract][Full Text] [Related]
14. Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality.
Möller HJ
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1101-11. PubMed ID: 14642970
[TBL] [Abstract][Full Text] [Related]
15. In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia.
Martinot JL; Paillère-Martinot ML; Poirier MF; Dao-Castellana MH; Loc'h C; Mazière B
Psychopharmacology (Berl); 1996 Mar; 124(1-2):154-8. PubMed ID: 8935811
[TBL] [Abstract][Full Text] [Related]
16. Differences in effects of sultopride and sulpiride on dopamine turnover in rat brain.
Moriuchi K; Imazu Y; Yoneda H
Neurochem Res; 1995 Jan; 20(1):95-9. PubMed ID: 7739765
[TBL] [Abstract][Full Text] [Related]
17. Is amisulpride an 'atypical' atypical antipsychotic agent?
Lecrubier Y
Int Clin Psychopharmacol; 2000 Dec; 15 Suppl 4():S21-6. PubMed ID: 11252520
[TBL] [Abstract][Full Text] [Related]
18. Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia.
Xiberas X; Martinot JL; Mallet L; Artiges E; Loc'H C; Mazière B; Paillère-Martinot ML
Br J Psychiatry; 2001 Dec; 179():503-8. PubMed ID: 11731352
[TBL] [Abstract][Full Text] [Related]
19. D2 receptor occupancy during high- and low-dose therapy with the atypical antipsychotic amisulpride: a 123I-iodobenzamide SPECT study.
la Fougère C; Meisenzahl E; Schmitt G; Stauss J; Frodl T; Tatsch K; Hahn K; Möller HJ; Dresel S
J Nucl Med; 2005 Jun; 46(6):1028-33. PubMed ID: 15937316
[TBL] [Abstract][Full Text] [Related]
20. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials.
Leucht S
Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S15-20. PubMed ID: 14972080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
